Calcitonin gene-related peptide (receptor) antibodies: an exciting avenue for migraine treatment

Antoinette MaassenVanDenBrink; Gisela M Terwindt; Arn M J M van den Maagdenberg

doi:10.1186/s13073-018-0524-7

Calcitonin gene-related peptide (receptor) antibodies: an exciting avenue for migraine treatment

Genome Med. 2018 Feb 22;10(1):10. doi: 10.1186/s13073-018-0524-7.

Authors

Antoinette MaassenVanDenBrink¹, Gisela M Terwindt², Arn M J M van den Maagdenberg^{3

4}

Affiliations

¹ Department of Internal Medicine, Division of Vascular Medicine and Pharmacology, Erasmus MC, Rotterdam, The Netherlands.
² Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands.
³ Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands. A.M.J.M.van_den_Maagdenberg@lumc.nl.
⁴ Department of Human Genetics, Leiden University Medical Centre, Leiden, The Netherlands. A.M.J.M.van_den_Maagdenberg@lumc.nl.

Abstract

Specific prophylactic migraine treatments are urgently needed because of the unmet needs of many migraine patients. Antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor have recently shown efficacy in episodic and chronic migraine and will be available soon.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Calcitonin Gene-Related Peptide / metabolism
Humans
Migraine Disorders / drug therapy*
Molecular Targeted Therapy
Receptors, Calcitonin Gene-Related Peptide / immunology*
Receptors, Calcitonin Gene-Related Peptide / metabolism

Substances

Antibodies, Monoclonal
CALCA protein, human
Receptors, Calcitonin Gene-Related Peptide
Calcitonin Gene-Related Peptide